Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma — Anne‐Gaëlle Dosne (2022) | RDL Network
Population pharmacokinetics and exposure–response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma
Article 2022 en
Authors
AD
Anne‐Gaëlle Dosne
XL
Xia Li
ML
Man Luo
Abstract
1 min read
The PPK and E-R analyses support the daratumumab subcutaneous 1800 mg dosing regimen in combination with Pd for treatment of patients with RRMM. No dose adjustment is recommended in this indication for any of the investigated factors, none of which had clinically relevant effects on daratumumab PK.
Xuebing Xu, Sam Liao, Meletios A Dimopoulos, Pieter Sonneveld, P. Joy Ho, Andrew Belch, Merav Leiba, Marcelo Capra, David Gómez Gómez, Eva Medvedova, Shinsuke Iida, Chang‐Ki Min, Ming Qi, Jordan M. Schecter, Nushmia Z. Khokhar, Xiaoyu Yan, Liping Zhang, Pamela L. Clemens
Sagar Lonial, Hang Quach, Meletios A Dimopoulos, Paula Rodríguez‐Otero, Jesús G. Berdeja, Paul G. Richardson, Margee Kyada, Shuyu Chu, Min Chen, Patricia C. Abad, Juliane Morando, Niels W.C.J. van de Donk
Ying Ou, Sameer Doshi, Anh H. Nguyen, Fredrik Jönsson, Sanjay Aggarwal, Kanya Rajangam, Meletios A Dimopoulos, A. Keith Stewart, Ashraf Badros, Kyriakos P. Papadopoulos, David S. Siegel, Sundar Jagannath, Ravi Vij, Rubén Niesvizky, Richard Graham, Jenn Visich
Yan Li, Xiaomin Wang, Edward O’Mara, Meletios A Dimopoulos, Pieter Sonneveld, Katja Weisel, Jeffrey Matous, David S. Siegel, Jatin J. Shah, Elisabeth Kueenburg, Lars Sternås, Chloe Cavanaugh, Mohamed H. Zaki, Maria Palmisano, Simon Zhou
Discussion(0)
No comments yet. Be the first to comment.